SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Myriad Genetics, Inc. (MYGN) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (2190)10/21/2008 1:22:38 PM
From: scaram(o)uche1 Recommendation  Respond to of 2355
 
1. Myriad was born a proteomics company, home of two-hybrid.

Here's what's left.....

prolexys.com

2. Anyone who has read this thread knows that the development of flurbie was coordinated by clowns. The Chief Clown, Hobden, brought us the first "pivotal" phase III design and the projected line on paper that served as control for the highly promoted phase II (the one that failed). I watched the project from the TRAMP mouse on, and understand the convoluted logic that was used to keep R-flurbiprofen alive. These men are tacky and greedy, and that's about it.



To: mopgcw who wrote (2190)10/21/2008 2:01:15 PM
From: FiloF  Respond to of 2355
 
Thank you. I was thinking the same thing but assumed I just don't know what I am thinking about <g>. Seems like a perfect setup for a biotech co. - to have a cash cow funding the cash-draining business.

They say they want to "unlock the intrinsic value of both business opportunities." I guess those 3,923,039 shares held by executive officers and directors needed unlocking.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News